Your browser doesn't support javascript.
loading
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.
Martinez, Francisco J; White, Michael; Guillotte-Blisnick, Micheline; Huon, Christèle; Boucharlat, Alix; Agou, Fabrice; England, Patrick; Popovici, Jean; Hou, Mimi M; Silk, Sarah E; Barrett, Jordan R; Nielsen, Carolyn M; Reimer, Jenny M; Mukherjee, Paushali; Chauhan, Virander S; Minassian, Angela M; Draper, Simon J; Chitnis, Chetan E.
Afiliación
  • Martinez FJ; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France.
  • White M; Infectious Disease Epidemiology and Analytics G5 Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • Guillotte-Blisnick M; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France.
  • Huon C; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France.
  • Boucharlat A; Chemogenomic and Biological Screening Core Facility, C2RT, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, Paris, France.
  • Agou F; Chemogenomic and Biological Screening Core Facility, C2RT, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, Paris, France.
  • England P; Molecular Biophysics Facility, CNRS UMR 3528, Institut Pasteur, Paris, France.
  • Popovici J; Malaria Reasearch Unit, Institut Pasteur du Cambodge, Pnom Penh, Cambodia.
  • Hou MM; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
  • Silk SE; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
  • Barrett JR; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK.
  • Nielsen CM; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
  • Reimer JM; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
  • Mukherjee P; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK.
  • Chauhan VS; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
  • Minassian AM; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
  • Draper SJ; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK.
  • Chitnis CE; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
NPJ Vaccines ; 9(1): 10, 2024 Jan 06.
Article en En | MEDLINE | ID: mdl-38184681
ABSTRACT
The receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein (PvDBPII) binds the Duffy antigen on the reticulocyte surface to mediate invasion. A heterologous vaccine challenge trial recently showed that a delayed dosing regimen with recombinant PvDBPII SalI variant formulated with adjuvant Matrix-MTM reduced the in vivo parasite multiplication rate (PMR) in immunized volunteers challenged with the Thai P. vivax isolate PvW1. Here, we describe extensive analysis of the polyfunctional antibody responses elicited by PvDBPII immunization and identify immune correlates for PMR reduction. A classification algorithm identified antibody features that significantly contribute to PMR reduction. These included antibody titre, receptor-binding inhibitory titre, dissociation constant of the PvDBPII-antibody interaction, complement C1q and Fc gamma receptor binding and specific IgG subclasses. These data suggest that multiple immune mechanisms elicited by PvDBPII immunization are likely to be associated with protection and the immune correlates identified could guide the development of an effective vaccine for P. vivax malaria. Importantly, all the polyfunctional antibody features that correlated with protection cross-reacted with both PvDBPII SalI and PvW1 variants, suggesting that immunization with PvDBPII should protect against diverse P. vivax isolates.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2024 Tipo del documento: Article País de afiliación: Francia